Oppenheimer raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $31 from $29 and keeps an Outperform rating on the shares.

Pharmaceutical Industries announced that the companies have entered into a license, development and commercialization agreement for EPYSQLI, Samsung Bioepis’ biosimilar to Soliris in the United States ...

U.S. President-elect Donald Trump will not go to jail or face any other punishment for his criminal conviction stemming from hush money paid to a porn star, a judge ruled on Friday but said Trump ...

Whether you’re a fan of the All Blacks, a follower of the women’s game or someone who watches every phase of play in the Premiership, our rugby features and news pieces will provide you with all of ...